Skip to main content

CCTG Connection



Published:
Category: Publications
Publication:  SRC6 two sub-studys
Two SRC6 sub studies: The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma and the Identified enrollment challenges of adolescent and young adult patients on the nonchemotherapy arm Read More

Published:
Category: Publications
Publication: secondary analysis MAC4 MAC15 and PRC3
MAC27
Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets
El Kababji S, Mitsakakis N, Fang X, Beltran-Bless A-A, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow WE, Gralow J, Savard M-F, Clemons M, Emam KE. Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets. JCO Clinical Cancer Informatics e2300116.
Read More

Published:
Category: Trials
The new trial ALC8 has opened, testing new treatments for acute myeloid leukemia

The recently opened ALC8 treatment trial will be testing the effects of novel therapeutics for newly diagnosed, untreated patients with acute myeloid leukemia (AML). Researchers want to compare the usual treatment for high-risk AML with four different combinations of treatment. 

Read More

Published:
Category: Trials
Trial closure: BLC1
Permanent closure for the BLC1 randomized phase II trial studying standard pelvic lymphadenectomy for invasive bladder cancer. Read More



Published:
Category: Group updates
Patient Representative Committee - goodby to Judy Needham  Michelle Audoin has accepted the role of Chair

Change often comes with both excitement and the inevitable goodbye. 

Read More

Published:
Category: News
La période d’inscription à l’essai novateur sur le mélanome ME17 est commencée.

La Dre Rahima Jamal et Camille Amiel préparent le patient à prendre les capsules de microbiote fécal. Photo : Centre hospitalier de l’Université de Montréal (CHUM)

Read More

Published:
Category: Publications
Publication: NCI General Review

NCI Precision Medicine Trials

Newer approaches employing combinations of targeted therapy, or targeted therapy with standard therapies, need to be considered. The NCI embarked on three second-generation precision medicine trials to address this need: ComboMATCH, iMATCH, and myeloMATCH. The design of these trials and necessary infrastructure are discussed in the following perspective.

Read More

Published:
Category: Publications
IND general review publications
Three IND general review publications, Accelerating the Future of Oncology Drug Development, CONSORT-DEFINE explanation and elaboration, and SPIRIT-DEFINE explanation and elaboration. Read More